Kura Oncology to Report Third Quarter Financial Results on November 10

Kura Oncology (Nasdaq: KURA) will report its third quarter 2026 financial results after market close on November 10, 2026.

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) will report its third quarter 2026 financial results after market close on November 10, 2026.

Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update. A live webcast and archived replay will be available in the Events and Presentations section of the Investors tab on the company’s website.

Key Figures

Results reporting date: November 10, 2026

Results reporting date

November 10, 2026

Third quarter 2026 financial results, after market close

Key Terms

menin inhibitor, NPM1-mutated acute myeloid leukemia, farnesyl transferase inhibition

3 terms

menin inhibitor medical

"the FDA-approved once-daily, oral menin inhibitor"

A menin inhibitor is a type of experimental drug that blocks the action of a protein called menin, which some cancers use to keep growing. Think of it as flipping off a switch that cancer cells rely on to survive; by doing so, these drugs can slow or stop tumor growth. Investors watch menin inhibitors because clinical trial results, regulatory approvals, and market demand determine whether they become valuable cancer treatments and potential revenue drivers.

NPM1-mutated acute myeloid leukemia medical

"adults with relapsed or refractory NPM1-mutated acute myeloid leukemia"

A subtype of acute myeloid leukemia (AML) defined by a mutation in the NPM1 gene, which alters how blood-cell precursors behave and is detected by genetic testing. It matters to investors because the presence of this mutation affects prognosis, which patients are eligible for particular therapies or clinical trials, and therefore shapes drug development strategies, market size estimates, and regulatory pathways—similar to how a specific defect in a car model determines repair options and parts demand.

farnesyl transferase inhibition medical

"advancements in menin inhibition and farnesyl transferase inhibition"

Blocking the enzyme farnesyl transferase, which normally attaches a small lipid “farnesyl” tag to certain proteins so they can stick to cell membranes and send growth signals. Think of it like preventing a postage stamp from being added so a letter can’t be delivered to the right address. As a drug mechanism, it matters to investors because clinical trial outcomes, safety data, and regulatory decisions about these inhibitors can materially affect the value of companies developing them.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will report its third quarter 2026 financial results after market close on Tuesday, November 10, 2026.

Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update.

The live webcast and archived replay of the event will be available in the Events and Presentations section of the Investors tab on the Company’s website at www.kuraoncology.com.

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI^® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us X and LinkedIn.

Kura Contact

Investors and Media:
Greg Mann
gmann@kuraoncology.com